×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AUTL – autolus therapeutics plc - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AUTL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/5
02:43 am
autl
Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026 [Yahoo! Finance]
High
Report
Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026 [Yahoo! Finance]
2/24
07:00 am
autl
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Autolus Therapeutics to Participate in Upcoming Investor Conferences
2/17
07:17 am
autl
Autolus Therapeutics (NASDAQ:AUTL) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Medium
Report
Autolus Therapeutics (NASDAQ:AUTL) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
2/16
10:15 am
autl
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
Medium
Report
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
2/16
10:15 am
autl
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
Medium
Report
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
2/4
08:57 am
autl
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/23
06:56 am
autl
Autolus Therapeutics (NASDAQ:AUTL) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Autolus Therapeutics (NASDAQ:AUTL) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/23
05:06 am
autl
Autolus Therapeutics (NASDAQ:AUTL) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Autolus Therapeutics (NASDAQ:AUTL) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
07:00 am
AUTL
autolus therapeutics plc - american depositary shares
MISS
Report
-2.9%
autolus therapeutics plc - american depositary shares
8/12/2025
07:00 am
AUTL
autolus therapeutics plc - american depositary shares
BEAT
Report
-0.4%
autolus therapeutics plc - american depositary shares
5/8/2025
07:00 am
AUTL
autolus therapeutics plc - american depositary shares
MISS
Report
2.3%
autolus therapeutics plc - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/17
09:52 pm
autl
Form SCHEDULE 13G/A Autolus Therapeutics Filed by: ARMISTICE CAPITAL, LLC
Medium
Report
Form SCHEDULE 13G/A Autolus Therapeutics Filed by: ARMISTICE CAPITAL, LLC
2/13
04:09 pm
autl
Form SCHEDULE 13G/A Autolus Therapeutics Filed by: MAK Capital Fund LP
Medium
Report
Form SCHEDULE 13G/A Autolus Therapeutics Filed by: MAK Capital Fund LP
1/26
04:09 pm
autl
Form 424B3 Autolus Therapeutics
Low
Report
Form 424B3 Autolus Therapeutics
1/26
04:08 pm
autl
Form 8-K Autolus Therapeutics For: Jan 21
Low
Report
Form 8-K Autolus Therapeutics For: Jan 21
1/12
08:38 am
autl
Form 424B3 Autolus Therapeutics
High
Report
Form 424B3 Autolus Therapeutics
1/12
08:36 am
autl
Form 8-K Autolus Therapeutics For: Jan 12
High
Report
Form 8-K Autolus Therapeutics For: Jan 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/25
Visiongain Report Looks at Opportunities Within the $23bn Cell Therapy Technologies Market
18.8%
3/3 Autolus Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Progress 6.7%
5/14 Q1/2019 3/31/2019 EPS -0.690 ZacksConsensus -0.580 ActVsEst (0.110) - Miss 6.5%
12/7 Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers 6.4%
11/5 Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting 6.0%
4/14 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) - Global Market Insights and Forecast to 2030 - ResearchAndMarkets.com 5.7%
3/19 Autolus Therapeutics (AUTL) Investor Presentation - Slideshow [Seeking Alpha] 5.4%
2/13 The Alliance for Regenerative Medicine Releases Agenda for 2020 Cell & Gene Meeting on the Mediterranean 4.9%
4/21 Autolus Therapeutics Ltd - (NASDAQ: AUTL) is now covered by analysts at Mizuho. They set a "buy" rating on the stock. 4.7%
10/9 3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting [The Motley Fool] 4.6%
3/3 Autolus Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Progress 6.7%
5/14 Q1/2019 3/31/2019 EPS -0.690 ZacksConsensus -0.580 ActVsEst (0.110) - Miss 6.5%
12/7 Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers 6.4%
11/5 Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting 6.0%
4/14 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) - Global Market Insights and Forecast to 2030 - ResearchAndMarkets.com 5.7%
3/19 Autolus Therapeutics (AUTL) Investor Presentation - Slideshow [Seeking Alpha] 5.4%
2/13 The Alliance for Regenerative Medicine Releases Agenda for 2020 Cell & Gene Meeting on the Mediterranean 4.9%
4/21 Autolus Therapeutics Ltd - (NASDAQ: AUTL) is now covered by analysts at Mizuho. They set a "buy" rating on the stock. 4.7%
10/9 3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting [The Motley Fool] 4.6%
TOP News Decliners
1/22
Autolus Announces Proposed Public Offering in the United States
-14.6%
8/9 Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -13.6%
8/8 Form 6-K Autolus Therapeutics For: Jun 30 -13.0%
8/8 Q2/2019 6/30/2019 EPS -0.650 ZacksConsensus -0.760 ActVsEst 0.110 - Beat -12.1%
3/9 Maryland Tech Council Announces the Finalists for the Industry Awards Celebration -11.0%
5/7 Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14 -8.1%
2/25 Autolus Therapeutics to Present at the Cowen 40th Annual Health Care Conference -8.1%
9/9 Form SC 13G/A Autolus Therapeutics Filed by: Woodford Patient Capital Trust Plc -7.8%
2/18 Cell Therapy Manufacturing Market Landscape & Opportunity Assessment, 2019-2030 -7.2%
11/12 Autolus Therapeutics Ltd - (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. -6.0%
8/9 Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -13.6%
8/8 Form 6-K Autolus Therapeutics For: Jun 30 -13.0%
8/8 Q2/2019 6/30/2019 EPS -0.650 ZacksConsensus -0.760 ActVsEst 0.110 - Beat -12.1%
3/9 Maryland Tech Council Announces the Finalists for the Industry Awards Celebration -11.0%
5/7 Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14 -8.1%
2/25 Autolus Therapeutics to Present at the Cowen 40th Annual Health Care Conference -8.1%
9/9 Form SC 13G/A Autolus Therapeutics Filed by: Woodford Patient Capital Trust Plc -7.8%
2/18 Cell Therapy Manufacturing Market Landscape & Opportunity Assessment, 2019-2030 -7.2%
11/12 Autolus Therapeutics Ltd - (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: